005690.KS
Pharmicell Co., Ltd. [005690.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
005690.KS Stock Summary
Top 10 Correlated ETFs
005690.KS
Top 10 Correlated Stocks
005690.KS
In the News
005690.KS Financial details
Company Rating
Buy
Market Cap
343.22B
Income
-1.71B
Revenue
54.95B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
05 Feb 2024
P/E
-194.07
Forward P/E
-
PEG
16.48
P/S
6.2
P/B
4.05
P/C
-
P/FCF
52.26
Quick Ratio
2.02
Current Ratio
3.41
Debt / Equity
0.06
LT Debt / Equity
0
-
-
EPS (TTM)
-28.05
EPS next Y
-
EPS next Q
-
EPS this Y
14.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
16.25%
Revenue Q/Q
-31.42%
EPS Q/Q
78.4%
-
-
-
-
SMA20
-10.16%
SMA50
-25.07%
SMA100
-18.48%
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
-2%
ROC
0.01%
Gross Margin
29%
Oper. Margin
1%
Profit Margin
-3%
Payout
-
Shs Outstand
60M
Shs Float
54.3M
-
-
-
-
Target Price
-
52W Range
5660.0-12100.0
52W High
-53.06%
52W Low
+0.35%
RSI
29
Rel Volume
-
Avg Volume
321.36K
Volume
Perf Week
-5.65%
Perf Month
-9.98%
Perf Quarter
-27.55%
Perf Half Y
-35.6%
-
-
-
-
Beta
-0.848
-
-
Volatility
84.76%, 336.28%
Prev Close
-0.7%
Price
5680
Change
-0.87%
005690.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 478.46 | 545.46 | 629.77 | 850.84 | 1K | |
| Net income per share | -214 | 73 | 87.44 | 159.04 | 181.58 | |
| Operating cash flow per share | 57.46 | -1.27 | 149.77 | -87.3 | 132.03 | |
| Free cash flow per share | -21.47 | -29.18 | 137.38 | -159.53 | -184.22 | |
| Cash per share | 348.53 | 315.68 | 432.89 | 605.92 | 433.05 | |
| Book value per share | 801.43 | 865.15 | 952.61 | 1.09K | 1.33K | |
| Tangible book value per share | 687.85 | 746.65 | 847.43 | 988.31 | 1.23K | |
| Share holders equity per share | 801.43 | 865.15 | 952.61 | 1.09K | 1.33K | |
| Interest debt per share | 51.59 | 53.42 | 52.56 | 316.49 | 293.44 | |
| Market cap | 758.48B | 505.58B | 1037.07B | 780.6B | 644.42B | |
| Enterprise value | 742.89B | 491.95B | 1019.19B | 771.63B | 646.9B | |
| P/E ratio | -59.81 | 116.3 | 197.85 | 82.05 | 59.2 | |
| Price to sales ratio | 26.75 | 15.56 | 27.47 | 15.34 | 10.71 | |
| POCF ratio | 222.76 | -6.7K | 115.51 | -149.48 | 81.42 | |
| PFCF ratio | -596.1 | -290.94 | 125.93 | -81.8 | -58.35 | |
| P/B Ratio | 15.97 | 9.81 | 18.16 | 11.94 | 8.08 | |
| PTB ratio | 15.97 | 9.81 | 18.16 | 11.94 | 8.08 | |
| EV to sales | 26.2 | 15.15 | 27 | 15.16 | 10.75 | |
| Enterprise value over EBITDA | 348.89 | 112.1 | 131.12 | 66.37 | 47.27 | |
| EV to operating cash flow | 218.18 | -6.52K | 113.52 | -147.76 | 81.74 | |
| EV to free cash flow | -583.85 | -283.1 | 123.76 | -80.86 | -58.58 | |
| Earnings yield | -0.02 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0 | 0 | 0.01 | -0.01 | -0.02 | |
| Debt to equity | 0.06 | 0.06 | 0.05 | 0.26 | 0.21 | |
| Debt to assets | 0.05 | 0.05 | 0.04 | 0.18 | 0.15 | |
| Net debt to EBITDA | -7.32 | -3.1 | -2.3 | -0.77 | 0.18 | |
| Current ratio | 9.79 | 6.27 | 6.6 | 2.67 | 2.18 | |
| Interest coverage | 4.58 | 19.38 | 85.21 | 4.52 | 11.89 | |
| Income quality | -0.27 | -0.02 | 1.71 | -0.55 | 0.73 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.03 | |
| Research and developement to revenue | 0.16 | 0.15 | 0.11 | 0.14 | 0.11 | |
| Intangibles to total assets | 0.11 | 0.11 | 0.09 | 0.07 | 0.05 | |
| Capex to operating cash flow | -1.37 | 22.02 | -0.08 | 0.83 | -2.4 | |
| Capex to revenue | -0.16 | -0.05 | -0.02 | -0.08 | -0.32 | |
| Capex to depreciation | -2.88 | -0.93 | -0.42 | -2.49 | -8.68 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.96K | 1.19K | 1.37K | 1.98K | 2.33K | |
| ROIC | 0 | 0.06 | 0.1 | 0.09 | 0.17 | |
| Return on tangible assets | -0.24 | 0.08 | 0.08 | 0.11 | 0.1 | |
| Graham Net | 280.01 | 309.37 | 433.82 | 431.43 | 268.61 | |
| Working capital | 29.21B | 29.13B | 36.43B | 41.58B | 33.82B | |
| Tangible asset value | 40.76B | 44.46B | 50.8B | 59.12B | 73.55B | |
| Net current asset value | 20.91B | 22.91B | 30.3B | 36.06B | 29.38B | |
| Invested capital | 0.06 | 0.06 | 0.05 | 0.26 | 0.21 | |
| Average receivables | 6.78B | 8.09B | 11.19B | 14.07B | 15.52B | |
| Average payables | 891.39M | 832.01M | 1.29B | 1.4B | 1.75B | |
| Average inventory | 5.41B | 6.8B | 7.28B | 11.61B | 19.88B | |
| Days sales outstanding | 83.74 | 108.74 | 122.8 | 110.72 | 94.57 | |
| Days payables outstanding | 23.47 | 11.26 | 36.04 | 11.14 | 26.66 | |
| Days of inventory on hand | 118.57 | 154.37 | 115.83 | 224.7 | 229.47 | |
| Receivables turnover | 4.36 | 3.36 | 2.97 | 3.3 | 3.86 | |
| Payables turnover | 15.55 | 32.41 | 10.13 | 32.75 | 13.69 | |
| Inventory turnover | 3.08 | 2.36 | 3.15 | 1.62 | 1.59 | |
| ROE | -0.27 | 0.08 | 0.09 | 0.15 | 0.14 | |
| Capex per share | -78.93 | -27.91 | -12.39 | -72.23 | -316.25 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 287.88 | 200.13 | 225 | 308.31 | 0 | |
| Net income per share | 64.64 | -74.48 | 18.59 | 10 | 0 | |
| Operating cash flow per share | 55.98 | 2.8 | 50.5 | 83.27 | 0 | |
| Free cash flow per share | -127.73 | -6.18 | 41.63 | 66.59 | 0 | |
| Cash per share | 474.72 | 435.48 | 489.46 | 527.34 | 0 | |
| Book value per share | 1.38K | 1.34K | 1.38K | 1.41K | 0 | |
| Tangible book value per share | 1.27K | 1.23K | 1.28K | 1.3K | 0 | |
| Share holders equity per share | 1.38K | 1.34K | 1.38K | 1.41K | 0 | |
| Interest debt per share | 315.16 | 313.99 | 289.22 | 276.09 | 0 | |
| Market cap | 617.44B | 640.83B | 531.79B | 428.73B | 0 | |
| Enterprise value | 623.11B | 643.31B | 531.14B | 421.21B | -14.1B | |
| P/E ratio | 39.84 | -36.08 | 122.77 | 186.25 | 0 | |
| Price to sales ratio | 35.78 | 53.71 | 40.58 | 24.16 | 0 | |
| POCF ratio | 184 | 3.84K | 180.8 | 89.47 | 0 | |
| PFCF ratio | -80.64 | -1.74K | 219.32 | 111.89 | 0 | |
| P/B Ratio | 7.49 | 8.04 | 6.61 | 5.29 | 0 | |
| PTB ratio | 7.49 | 8.04 | 6.61 | 5.29 | 0 | |
| EV to sales | 36.11 | 53.92 | 40.53 | 23.74 | -1.16 | |
| Enterprise value over EBITDA | 172.89 | -288.87 | 136.41 | 328.28 | -11.55 | |
| EV to operating cash flow | 185.69 | 3.86K | 180.58 | 87.9 | -7.51 | |
| EV to free cash flow | -81.38 | -1.75K | 219.05 | 109.92 | -22.26 | |
| Earnings yield | 0.01 | -0.01 | 0 | 0 | 0 | |
| Free cash flow yield | -0.01 | 0 | 0 | 0.01 | 0 | |
| Debt to equity | 0.24 | 0.21 | 0.21 | 0.2 | 0.06 | |
| Debt to assets | 0.17 | 0.15 | 0.15 | 0.14 | 0.04 | |
| Net debt to EBITDA | 1.57 | -1.12 | -0.17 | -5.86 | -11.55 | |
| Current ratio | 2.67 | 2.18 | 2.2 | 2.4 | 3.41 | |
| Interest coverage | -3.71 | -0.42 | -0.82 | 0 | 0 | |
| Income quality | 0.87 | -1.09 | 4.21 | 8.33 | 1.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.27 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.08 | 0.19 | 0.13 | 0.11 | 0.12 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | |
| Capex to operating cash flow | -3.28 | -3.21 | -0.18 | -0.2 | -0.66 | |
| Capex to revenue | -0.64 | -0.04 | -0.04 | -0.05 | -0.1 | |
| Capex to depreciation | -18.04 | -0.75 | -0.74 | -1.36 | -1.76 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.41K | 1.5K | 760.1 | 562.74 | 0 | |
| ROIC | 0.04 | -0.01 | 0 | 0.01 | 0.01 | |
| Return on tangible assets | 0.04 | -0.04 | 0.01 | 0.01 | 0.01 | |
| Graham Net | 385.75 | 270.12 | 260.78 | 318.63 | 0 | |
| Working capital | 41.59B | 33.82B | 34.68B | 35.26B | 35.84B | |
| Tangible asset value | 76.29B | 73.55B | 74.29B | 74.85B | 75.92B | |
| Net current asset value | 35.69B | 29.38B | 30.12B | 30.61B | 31.02B | |
| Invested capital | 0.24 | 0.21 | 0.21 | 0.2 | 0.06 | |
| Average receivables | 21.88B | 19.1B | 13.28B | 10.13B | 9.87B | |
| Average payables | 2.8B | 2.97B | 2.79B | 2.39B | 2.21B | |
| Average inventory | 16.35B | 19.91B | 23.35B | 22.82B | 21.8B | |
| Days sales outstanding | 117.94 | 117.63 | 75.37 | 47.14 | 77.23 | |
| Days payables outstanding | 26.38 | 30.46 | 28.67 | 12.32 | 26.88 | |
| Days of inventory on hand | 136.51 | 262.2 | 232.93 | 146.18 | 227.3 | |
| Receivables turnover | 0.76 | 0.77 | 1.19 | 1.91 | 1.17 | |
| Payables turnover | 3.41 | 2.95 | 3.14 | 7.31 | 3.35 | |
| Inventory turnover | 0.66 | 0.34 | 0.39 | 0.62 | 0.4 | |
| ROE | 0.05 | -0.06 | 0.01 | 0.01 | 0.01 | |
| Capex per share | -183.71 | -8.98 | -8.87 | -16.68 | 0 |
005690.KS Frequently Asked Questions
What is Pharmicell Co., Ltd. stock symbol ?
Pharmicell Co., Ltd. is a KR stock and trading under the symbol 005690.KS
What is Pharmicell Co., Ltd. stock quote today ?
Pharmicell Co., Ltd. stock price is $5680 today.
Is Pharmicell Co., Ltd. stock public?
Yes, Pharmicell Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 321.36K
- Market Capitalization 343.22B
- CEO Hyun-Soo Kim
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.pharmicell.com 
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
